259810-12-3

Basic information

• Product Name: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE
• Synonyms: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-AMINE;6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE;6,7-dihydro-4H-pyrano[4,3-d][1,3]thiazol-2-amine;6,7-Dihydro-4H-pyrano[4,3-d]-1,3-thiazol-2-ylamine;4H,6H,7H-pyrano[4,3-d][1,3]thiazol-2-aMine
• CAS NO: 259810-12-3
• Molecular Formula: C₆H₈N₂OS
• Molecular Weight: 156.20552
• Product Categories: pharmacetical
• Mol File: 259810-12-3.mol

Chemical Properties

• Boiling Point: 353.65 °C at 760 mmHg
• Flash Point: 167.682 °C
• Appearance: /
• Density: 1.391 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.646
• PKA: 4.73±0.20(Predicted)
• CAS DataBase Reference: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(259810-12-3)
• EPA Substance Registry System: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(259810-12-3)

Safety Data

• Hazardous Substances Data: 259810-12-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is used as a pharmaceutical intermediate for the synthesis of various organic compounds. Its unique structure and potential biological activities make it a promising candidate for the development of new drugs.
Used in Antimicrobial Applications:
6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is used as an antimicrobial agent due to its potential to inhibit the growth of certain microorganisms. Its effectiveness in combating bacterial infections can contribute to the development of new antimicrobial therapies.
Used in Antifungal Applications:
6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is used as an antifungal agent, exhibiting the ability to prevent the growth of fungi. This property can be harnessed in the creation of antifungal medications to treat fungal infections.
Used in Antitumor Applications:
6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is used as an antitumor agent, showing potential in inhibiting the growth of tumor cells. Its antitumor properties can be explored for the development of cancer treatments, offering new therapeutic options for patients.
Used in Organic Chemistry Research:
6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is used as a building block in organic chemistry, facilitating the synthesis of complex organic compounds. Its unique structure and potential reactivity make it a valuable tool for researchers in the field of organic chemistry.

InChI:InChI=1/C6H8N2OS/c7-6-8-4-1-2-9-3-5(4)10-6/h1-3H2,(H2,7,8)

Upstream product

• 62936-76-9 1-(3,6-dihydro-2H-pyran-4-yl)pyrrolidine 
• 420-04-2 CYANAMID 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 123-75-1 pyrrolidine 
• 17356-08-0 thiourea 
• 160427-98-5 3-chlorodihydro-2H-pyran-4(3H)-one 
• 98021-79-5 3-bromo-tetrahydro-pyran-4-one 

Downstream Products

• 1083177-70-1 (Z)-5-chloro-N-(6,7-dihydro-1H-pyrano[4,3-d]thiazol-2(4H)-ylidene)-2-methoxybenzamide 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Provided are sulfonylaminopyridine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS

This invention relates to compounds that are of formula (I) wherein A is heteroaryl and R1 and R2 are both cyclic residues, that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases,

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.